Kiniksa Pharmaceuticals KNSA Stock
Kiniksa Pharmaceuticals Price Chart
Kiniksa Pharmaceuticals KNSA Financial and Trading Overview
| Kiniksa Pharmaceuticals stock price | 95.18 USD |
| Previous Close | 89.2 USD |
| Open | 88 USD |
| Bid | 67.21 USD x 200 |
| Ask | 112.96 USD x 200 |
| Day's Range | 87.54 - 95.28 USD |
| 52 Week Range | 36.56 - 95.28 USD |
| Volume | 1.7M USD |
| Avg. Volume | 625.57K USD |
| Market Cap | 7.32B USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 72.10606 |
| EPS (TTM) | 1.32 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 103.63 USD |
KNSA Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | 72.10606 |
| Forward P/E | 50.49337 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.741276 |
| Price/Book (mrq) | 12.793011 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Kiniksa Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 154.62% |
| S&P500 52-Week Change | 12.38% |
| 52 Week High | 95.28 USD |
| 52 Week Low | 36.56 USD |
| 50-Day Moving Average | 78.54 USD |
| 200-Day Moving Average | 59.65 USD |
KNSA Share Statistics
| Avg. Volume (3 month) | 625.57K USD |
| Avg. Daily Volume (10-Days) | 1.12M USD |
| Shares Outstanding | 46.3M |
| Float | 39.1M |
| Short Ratio | 6.53 |
| % Held by Insiders | 3.50% |
| % Held by Institutions | 102.31% |
| Shares Short | 3.76M |
| Short % of Float | 9.41% |
| Short % of Shares Outstanding | 4.82% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 11.58% |
| Operating Margin (ttm) | 18.96% |
| Gross Margin | 54.27% |
| EBITDA Margin | 13.99% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 945.96M USD |
| Revenue Per Share (ttm) | 12.27 USD |
| Quarterly Revenue Growth (yoy) | 58.09% |
| Gross Profit (ttm) | 513.39M USD |
| EBITDA | 132.35M USD |
| Net Income Avi to Common (ttm) | 109.57M USD |
| Diluted EPS (ttm) | 1.32 |
| Quarterly Earnings Growth (yoy) | 156.80% |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | 1.36 USD |
| Current Ratio (mrq) | N/A |
| Book Value Per Share (mrq) | 7.44 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Kiniksa Pharmaceuticals
| Country | United States |
| State | N/A |
| City | London |
| Address | 105 Piccadilly |
| ZIP | W1J 7NJ |
| Phone | 44 78 1431 9100 |
| Website | https://www.kiniksa.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 366 |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Q&A For Kiniksa Pharmaceuticals Stock
What is a current KNSA stock price?
Kiniksa Pharmaceuticals KNSA stock price today per share is 95.18 USD.
How to purchase Kiniksa Pharmaceuticals stock?
You can buy KNSA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kiniksa Pharmaceuticals?
The stock symbol or ticker of Kiniksa Pharmaceuticals is KNSA.
Which industry does the Kiniksa Pharmaceuticals company belong to?
The Kiniksa Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.
How many shares does Kiniksa Pharmaceuticals have in circulation?
The max supply of Kiniksa Pharmaceuticals shares is 76.94M.
What is Kiniksa Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Kiniksa Pharmaceuticals PE Ratio is 72.10606000 now.
What was Kiniksa Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Kiniksa Pharmaceuticals EPS is 1.32 USD over the trailing 12 months.
Which sector does the Kiniksa Pharmaceuticals company belong to?
The Kiniksa Pharmaceuticals sector is Healthcare.
Kiniksa Pharmaceuticals KNSA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
26549.85 USD — |
+0.27
|
7.14B USD — | 26414.92 USD — | 26587.34 USD — | — - | 7.14B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13074.13 USD — |
+0.25
|
— — | 13009.37 USD — | 13094.17 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7256.33 USD — |
+1.48
|
— — | 7065.77 USD — | 7269.93 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1368.59 USD — |
+1.45
|
— — | 1337.51 USD — | 1371.51 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
